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Report  
The Hay Wells Syndrome-Derived TAp63αQ540L Mutant Has Impaired
Transcriptional and Cell Growth Regulatory Activity
ABSTRACT
p63 mutations have been associated with several human hereditary disorders charac-
terized by ectodermal dysplasia such as EEC (ectrodactyly, ectodermal dysplasia, clefting)
syndrome, ADULT (acro, dermato, ungual, lacrimal, tooth) syndrome and AEC (ankyloble-
pharon, ectodermal dysplasia, clefting) syndrome (also called Hay-Wells syndrome). The
location and functional effects of the mutations that underlie these syndromes reveal a
striking genotype-phenotype correlation. Unlike EEC and ADULT that result from missense
mutations in the DNA-binding domain of p63, AEC is solely caused by missense mutations
in the SAM domain of p63. In this paper we report a study on the TAp63α isoform, the
first to be expressed during development of the embryonic epithelia, and on its naturally
occurring Q540L mutant derived from an AEC patient. To assess the effects of the Q540L
mutation, we generated stable cell lines expressing TAp63α wt, ∆Np63α or the TAp63α-
Q540L mutant protein and used them to systematically compare the cell growth regulatory
activity of the mutant and wt p63 proteins and to generate, by microarray analysis, a
comprehensive profile of differential gene expression. We found that the Q540L substitution
impairs the transcriptional activity of TAp63α and causes misregulation of genes involved
in the control of cell growth and epidermal differentiation.
INTRODUCTION
The p63 protein is a transcription factor homolog of the p53 tumor suppressor. Unlike
p53, p63 functions primarily in epidermal-mesenchymal development during embryoge-
nesis. Mice in which p63 was inactivated displayed a fundamental defect in epithelial
lineage development and failed to develop stratified epithelia and epithelial appendages,
such as teeth, hair follicles and mammary glands.1,2 The role of p63 in the development
and differentiation of stratified epithelia, remains controversial. Indeed, recent studies
indicate that p63 may act as a molecular switch required for initiation of epithelial strati-
fication, or for maintaining the proliferative potential of basal keratinocytes in the mature
epidermis.3-5 It also seems to play a substantial role in the induction of apoptosis and
chemosensitivity.6-8
The p63 gene displays a high sequence and structural homology to p53.9 Like p53, the
p63 protein contains a transcriptional activator domain (TA) to induce transcription of
target genes, a DNA-binding (DB) domain and an oligomerization domain (OD), used
to form tetramers.10 In contrast to p53, multiple protein products are produced by the
p63 gene. Two promoters are present at the 5' end of the gene. The first produces TA-p63
proteins, while transcription from the second creates ∆N-p63 products lacking the
aminoterminal TA domain. In addition three alternative splicing routes at the 3' end gen-
erate proteins with different C-termini, denoted α, β and γ. The TA and ∆Np63α isoforms
alone contain a Sterile Alpha Motif (SAM) domain absent in p53: this is the most remarkable
structural difference between p63 and p53. This domain is a 65–70 amino acid residue
sequence found in many proteins, from yeast to human, whose functions range from signal
transduction to transcriptional repression.11 It is a protein-protein interaction domain also
found in p73, another member of the p53 gene family, as well as in other developmentally
important proteins, such as several Eph receptor tyrosine kinases.12 Recent studies have
identified a transcriptional inhibitory (TI) domain located between the SAM domain and
the C-terminus of p63α isoforms that is believed to be responsible for the lack of transac-
tivation ability of TAα compared to TAβ and γ on several different p53 target promoters.13
The analysis of the functions of the multiple p63 isotypes are complicated by the existence
of several mechanisms regulating their expression levels. Such mechanisms are still under
investigation.14-19
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A broad spectrum of mutations found in several ectodermal,
craniofacial and limb syndromes, namely EEC (ectrodactyly,
ectodermal dysplasia, clefting), AEC (ankyloblepharon, ectodermal
dysplasia, clefting), LMS (limb-mammary syndrome), ADULT
(acro-dermato-ungual-lacrimal-tooth) and SHFM (split-hand/split-foot
malformation) have been mapped in distinct p63 domains.20
The location of mutations in the p63 protein domains and their
functional implications reveal a striking genotype-phenotype corre-
lation: EEC and ADULT result from missense mutations in the DB
domain and SHFM from mutations in either the DB or the C-ter-
minal domain,21 whereas AEC is solely caused by missense mutations
in the SAM domain. Unlike the other ectodermal dysplasia syndromes,
AEC does not comprise ectrodactyly or other major limb defects,
but has ankyloblepharon and severe scalp dermatitis as its distin-
guishing features.22
A p63 SAM-domain model structure has been used to divide the
naturally occurring AEC mutations into in two groups. The first
(L518V, I541T, C526W) includes mutations in amino acids that are
predicted to be buried inside the protein and are believed to affect
its overall structure and stability. The second (G534V, T537P and
Q540L), whose direct effect on the protein is less obvious, contains
all the other amino acids that have a larger solvent accessible surface
and are not predicted to cause gross conformational changes.22 These
AEC mutations may disrupt the structural integrity of the SAM
domain or interfere with particular protein-protein interactions.12
They have, in fact, already been shown to disrupt the interaction of
p63 with the Apobec-1 binding protein-1(ABPP1)23 and thus alter
the splicing mechanism of fibroblast growth factor receptor-2,
FGFR2.11
Here, we report data from a study on the TAp63α isoform, which
is the first to be expressed during the development of embryonic
epithelia,3 and on the AEC-derived TAp63αQ540L (1607 A to T)
mutant protein. This was described by Hay and Wells in their case
no. 5.24 It is located within exon 13 and is predicted do not destroy
the overall structure of the SAM domain.22
To study the effects of the Q540L mutation on p63 functions we
generated stable cell lines that express wild-type (wt) TAp63α,
∆Np63α or the TAp63αQ540L mutant under the control of a
TET-inducible promoter and used them to compare the effects of
the mutant and wt p63 proteins on cell proliferation and generate,
by microarray analysis, a comprehensive profile of differential gene
expression. We found that the Q540L substitution affects the tran-
scriptional activity of TAp63α and causes misregulation of genes
involved in the control of cell growth and epidermal differentiation.
MATERIALS AND METHODS
Plasmids. Wt p63α in pcDNA3-His expression vector has been
described.15 Mutation Q540L was created by PCR, using the NdeI site-
containing upstream primer, p63NdeI_FW (CCA TCT TCA TAT GGT
AAC AGC TCC CCA CCT C) and the downstream primer p63NcoI_RW
(ATC ATC CAT GGA GTA ATG CTC AAT CAG ATA GA) containing
the NcoI site and the substitution A → T that introduces the mutation. The
mutated fragment was replaced in the TAp63α wt sequence,15 digested with
NdeI/NcoI to generate the TAp63αQ540L sequence and then cloned in
pcDNA3.
To create the plasmids encoding the p63 proteins under the control of
the rtTA responsive promoter, the cDNA fragments were extracted from
pcDNA using Hind III and Xba I, blunted and cloned into the pBIG-βgal
Not I site. The pTet-On, pTK-Hyg, and pBIG-βgal constructs were provided
by Clontech. The Bp100CAT and p21/WAF/CAT reporter plasmids have
already been described.15,25
Cells, transfection and reporter assays. Human lung carcinoma H1299
cells (p53 null, no p63 expression) were obtained from the American Tissue
Culture Collection and grown at 37˚C in humidified 5% CO2 in DMEM
supplemented with 10% fetal calf serum. H1299 cells (5 x 104) were plated
and transfected by calcium-phosphate precipitation with 20 µg of pTet-On
plasmid (Clontech). Fourty-eight hours later, the cells were selected by
adding G418 (100 µg/ml) to the medium. After four weeks, single
G418-resistant clones (H1299-rtTA) were picked up and expanded. The
presence of the rtTA regulator in these clones was checked by performing a
β-galactosidase assay on H1299-rtTA cell extracts after transient transfection
with the pBGI-βgal empty construct, with or without doxycycline (Sigma-
Aldrich) (1 µg/ml).
Tet-On/TAp63α, Tet-On/∆Np63β, Tet-On/TAp63αQ540L cell lines
were produced as follows:
7 x 104 H1299-rtTA cells were cotransfected with each of the pBIG-p63
constructs and the pTK-Hygro vector (20 to 1 rate) by calcium-phosphate
precipitation. Twenty-four hours later, each 100 mm plate was split (1:2)
and cells were selected by adding 800 µg/ml hygromycin (Sigma-Aldrich).
After 4 weeks, single hygro-resistant clones were picked up and expanded,
and their p63-inducible gene expression was determined by Western blot
and specific immunodetection. p63 stable clones were maintained in DMEM
supplemented with 10% Tet-Approved serum (Hyclone). CAT assays with
the WAFCAT or BP100CAT reporter plasmids were performed as previously
described.16
Growth rate determination. Approximately 6 x 104 cells were seeded in
60 mm-diameter plates in the presence or absence of doxycycline (1 µg/ml)
for five days to regulate exogenous protein expression. Medium was replaced
every 48 hrs. At the indicated time points, two plates were rinsed twice with
PBS to remove dead cells and debris. Live cells on the plates were trypsinized
and collected separately. Cells from each plate were counted three times in
a Burker chamber. The average number from two plates was used to deter-
mine the growth rate.
DNA histogram analysis. Cells were counted and seeded at 2 x 105/
100 mm plate with or without doxycycline (1 µg/ml). At the indicated time
points, live cells on the plates were trypsinized and both floating dead cells
in the medium and trypsinized live cells were centrifuged and washed twice
with PBS. Approximately 106 cells were incubated in 1 ml of 0.1% Na citrate,
50 µg/ml propidium iodide (Sigma Chemical Co., St. Louis, MO, USA),
20 µg/ml RNase A and 0.1% Nonidet P-40. Cells were incubated for 40' at
RT in a dark box. Stained cells were analysed in a fluorescence-activated
cytometer (FACSCalibur-BD, Menlo Park, CA, USA) within 1 hr. Data on
DNA cell-content were acquired with the CellQuest program (Beckton-
Dickinson) on 20,000 events at a rate of 150 ± 50 events/second and the
percentages of cells in the SubG1, G0–G1, S and G2–M phases were quan-
tified with the ModFit software (Beckton-Dickinson). The percentage of
dead cells/total cells was determined by trypan blue dye staining. Briefly,
aliquots of cells were mixed with an equal volume of 0.4% trypan blue dye
solution (Sigma Chemical Co., St. Louis, MO, USA) and incubated for 15'
at RT. Stained (dead) and unstained (live) cells were counted with a hemo-
cytometer and the percentage of dead cells/total cells was determined by
scoring an average of over 300 cells, twice per plate.
Subcellular immunolocalization assay. Immunolocalization was performed
on doxycycline (1 µg/ml) induced or uninduced Tet-On cells, 105 cells/ 35 mm
plate were grown on micro cover glasses (BDH). Fourty-eight hours later,
cells were washed with cold phosphate-buffered saline (PBS) and fixed with
4% paraformaldehyde (Sigma-Aldrich), for 15' at 4˚C. After a rinse with
PBS, fixed cells were permeabilized with ice-cold 0.1% Triton X-100 for 10'
and rinsed again with PBS. Cells were than incubated with DAPI
(4,6-diamidino-2-phenylindole; 10 mg/ml Sigma-Aldrich) for 3' and washed
again with PBS. Lastly, the glasses were mounted with Moviol (Sigma-
Aldrich) and cells were examined under a fluorescence microscope (Nikon).
To detect p63 protein the H137 (Santa Cruz) and the CyTM 3-conjugated
anti-rabbit IgG (ImmunoResearch Laboratories) antibodies were used at RT
for 30'. Images were digitally processed with Adobe Photoshop software.
Western immunoblot analysis. At the indicated time after transfection,
cells were lysed in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5%
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Nonidet-P40, 10 mM glycerol, 5 mM EDTA, 0.5% NaDOC and 1 mM
PMSF. Proteins were separated on 8% SDS-PAGE and blotted onto PVDF
membrane. Filters were incubated with the following primary antibodies
MDM2 (SC-965; Santa Cruz); p63 (H137; Santa Cruz); p63 (4A4; Santa
Cruz); anti-p21/WAF1 (Ab-11, CP74; Neomarkers), actin (1-19; Santa Cruz);
anti-goat IgG/HRP (Santa Cruz); anti-mouse IgG/HRP (Amersham);
anti-rabbit IgG/HRP (Bio-Rad).
EMSA. EMSA experiments were performed as already described.26 P63
proteins were translated in vitro by using TnT reticulocytes from Promega
with 0.5 µg of p63 plasmid DNA. Next, 10 µl of the individual reactions
was used for the binding reaction and for Western blot analysis. The probe
is a radiolabeled oligonucleotide duplex containing a p53-binding site present
in the p21 promoter (p21.1 described in ref. 27). A 100-fold molar excess
of the same cold oligonucleotide or an oligonucleotide containing a consensus
binding site for E2F1 were used for competition experiments. For the super-
shift anti-p63 antibodies (4A4; SantaCruz) or unrelated polyclonal anti-p21
antibodies (C-19; SantaCruz) were added to the sample prior to the binding
reaction (30' in ice).
Microarray sample preparation. Total RNA (ttlRNA) was extracted and
purified from stably transfected H1299 cell lines with the Concert
Cytoplasmic RNA Purification Reagent (Invitrogen, Carlsbad, CA), as sug-
gested by the manufacturer. ttlRNAs were then quantified and inspected
with a Bioanalyzer (Agilent Technologies). cRNAs were generated and
hybridized on 12 HGU133plus2 Affymetrix DNA chips according to the
Affymetrix protocol, ttlRNA (8 µg) was used to prepare double-stranded
cDNA with the one-cycle cDNA synthesis kit (Affymetrix, USA). The
cDNA was then used as a template to synthesize a biotinylated cRNA (16 hr,
37˚C) with the IVT kit (Affymetrix, USA). In vitro transcription products
were purified with the IVT cleanup module and approximately 35 µg of
cRNA were treated with the fragmentation buffer (35' at 94˚C). Affymetrix
12 HGU133plus2 array chips were hybridized with biotinylated cRNA
(20 µg/chip, 16 hr, 45˚C using the hybridization buffer and control provided
by the manufacturer (Affymetrix Inc.). GeneChip Fluidics station 400
(Affymetrix Inc.) was used to wash and stain the arrays. The standard protocol
suggested by the manufacturer was used to detect the hybridized biotinylated
cRNA. The chips were then scanned with a specific scanner (Affymetrix
Inc.) to generate digitized image data (DAT) files.
Microarray data analysis. DAT files generated for the four prototypic
situations (TAp63α wt without induction, TAp63α wt with induction,
TAp63αQ540L without induction, TAp63αQ540L with induction) were
analyzed by GCOS (Affymetrix, USA) to generate background-normalized
image data (CEL files). The presence of hybridization/construction artifacts
was evaluated with the fitPLM function (Bioconductor package affyPLM).
The probes (PM) intensity distribution was evaluated using hist function
(Bioconductor package affy). Only one array from the TAp63αQ540L
with induction group was characterized by a narrow distribution of PM
intensities and was discarded.
Probe set intensities were obtained by means of GCRMA, a robust
multiarray analysis method (http://www.biostat.jhsph.edu/~ririzarr/papers/
p177-irizarry.pdf ).28 The full data set was normalized according to the
quantiles method.29 The HGU133plus2 54675 probe sets were filtered to
provide an interquantile range (IQR) for each probe set greater then 0.25.30
This filtering yielded 11857. Subsequently, “Significant analysis of microar-
rays” software (SAM-software)31 was used to identify probe sets differentially
expressed between wt and mutant p63 isoforms. Differentially expressed
probe sets were initially identified with the multi class method (900 permu-
tations, 50 false significants). This test requires one user-set parameter: a
threshold value that can be adjusted to maximize the number of significant
genes while minimizing the predicted false discovery rate. This analysis
produced 4000 differentially expressed probe sets, which were then filtered
to select those characterized by a fold change ≥ |2| between not-induced and
induced cell lines in wt or mutant experiments. This filtering yielded 100
probe set ids (Additional information Table A): 87 were associated with 81
Entrez Gene identifiers (gene ID)32 and the remaining 13 probe sets were
not assigned to any gene ID. The IQR filtered data set was also analysed
with two-class unpaired method, implemented in the SAM-software,31 to
highlight probe sets transactivated only by the wt or mutant isoforms. This
test requires two user-set parameters: a minimal fold change value and a
threshold value that can be adjusted to maximize the number of significant
genes while minimizing the predicted false discovery rate. We conducted a
blocked, two-class unpaired test using a 2-fold-change cut-off and a threshold
allowing a false significant number of about 1. This analysis produced 18
differentially expressed probe sets for TAp63α wt (16 upmodulated and 2
downmodulated) and 7 probe sets for the Q540L mutant isoform (1
upmodulated and 6 downmodulated) (Fig. 1, additional information Table B).
All these 18 probe sets included in sets identified as differentially expressed
with the multi class method. Since a certain amount of leaking, at tran-
scriptional level, of the tet-ON system was observed in our experiments
(data not shown), differential expression between not-induced and induced
cell lines could have been underestimated. Therefore, a two-class unpaired
test (2-fold-change cut-off and false significant number about 1) between
induced wt and mutant cell lines was also performed. The differentially
expressed probe sets were 441 (Additional information Table C).
To generate a robust set of differentially expressed genes for further
investigation, the intersection between the 100 probe sets derived from the
multi class test and the 441 from the two-class test was selected. This inter-
section contains 45 probe sets linked to 36 annotated genes and 7 unmapped
est (Fig. 3).
Overexpressed Gene Ontology Biological Process themes were searched
with the Bioconductor GOstats package.33 Gene annotation was performed
by using the Bioconductor annaffy library and the HGU133plus2 annotation
package (version 1.6.8).
Real-time RT quantitative PCR (qPCR) expression validation. Total
RNA was reverse transcribed to cDNA with the Omniscript RT Kit following
the manufacturer’s instructions (QIAGEN GmbH, Hilden, Germany,
EUROPE). The primer sequences are shown in Table 1. Primers were
designed by using the sequence identified by the Affymetrix identifier and
Primer Express 2.0 software (Applied Biosystems, Foster City, CA, USA).
Real-time quantitative PCR, 20 µl contained 2 µl of the cDNA, 1X SYBR
GREEN PCR Master Mix (PE Applied Biosystems, Foster City, CA, USA)
TAp63αQ540L Transcriptional Regulatory Activity
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Figure 1. Expression of p63 isoforms in H1299 stable clones. Western blot
analysis for detection of the p63 protein expression levels in Dox-inducible
H1299 cells. Cells were harvested at the indicated time points after induc-
tion with 1 µg/ml doxycycline. Equal amounts of soluble lysates (30 µg)
from uninduced and induced clones expressing wild-type TAp63α, ∆Np63α
or the mutant TAp63αQ540L protein were evaluated for p63 protein levels
by Western blotting using an anti-p63 antibody (4A4; Santa Cruz
Biotechnology).
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and 150 µM of each primer were performed with an ABI PRISM 7900HT
Sequence Detection System in the following cycle conditions: 50°C for 2
min, 95°C for 10 min., and 95˚C for 15 s followed by 60°C for 1 min 40
cycles. 384 plates were assembled by QIAGEN 8000 BIOROBOT (QIA-
GEN GmbH, Hilden, Germany, EUROPE). Negative cDNA controls (no
cDNA) were cycled in parallel with each run. Fluorescence data were analyzed
with the SDS 2.1 software (Applied Biosystems, Foster City, CA, USA) and
expressed as Ct, the number of cycles needed to generate a fluorescent signal
above a predefined threshold. Target gene mRNA levels were expressed as
2-∆Ct, normalized for ACTB and POL2B, and fold changes were evaluates
as 2-∆∆Ct with the corresponding noninduced cell line as the calibrator
according to Livak and Schmittgen.34
Additional informations. Probe sets intensities and additional information
tables are available at http://www.bioinformatica.unito.it/bioinformatics/p63.
RESULTS
Production of TAp63α, TAp63αQ540L and ∆Np63α stable cell lines.
To investigate the effects of the Q540L mutation on p63 protein functions,
we generated stable H1299 cell lines, expressing TAp63α, ∆Np63α or
TAp63αQ540L, under a tetracycline/doxycycline (Dox)-inducible promoter
(see materials and methods). H1299 cells are p53 negative and show no
detectable levels of p63 and/or p73 (and data not shown).35
We first analysed by Western blot the timing and level of expression of
TAp63α wt, TAp63αQ540L and ∆Np63α proteins in our clones upon Dox
induction. Results from representative cell lines for TAp63α wt,
TAp63αQ540L and ∆Np63α are shown in Figure 1. Without Dox in the
medium, p63 proteins were undetectable. Addition of 1 µg/ml Dox led to
time-dependent induction of p63 proteins (Fig. 1). At 24 hrs of induction,
p63 proteins were already abundant and their expression levels were com-
parable as shown by immunodetection of actin as a loading control (data not
shown).
TAp63αQ540L is unable to induce a G1 cell cycle arrest. We first
decided to test the effects of wt TAp63α, ∆Np63α and mutant TAp63α-
Q540L protein on H1299 cell proliferation. TA and ∆Np63α were already
known to induce H1299 cell cycle arrest and apoptosis, though to a different
extent.35 According to these data, H1299 cells, expressing wt TAp63α or
∆Np63α showed a reduction of cell growth rate while non-induced cells
grew normally (Fig. 2A and B). The cell growth profile was completely
unaffected by TAp63αQ540L expression (Fig. 2C). The trypan blue dye
exclusion assay showed that TAp63α expression induced 9.2% of cell death
and ∆Np63α 3.4 % 72 hr after induction, whereas TAp63αQ540L had
completely lost this ability (Fig. 2D). Our p63-inducible clones were then
examined by flow cytometry. In a Dox-free culture medium, the three p63
stable cell lines and the parental H1299 cell lines maintained a similar cell
cycle phase distribution of DNA content (Fig. 2E and data not shown). At
48 hr, addition of 1 µg/ml of Dox resulted in G1 cell cycle arrest by both wt
TA and ∆Np63α with a parallel reduction in S and G2/M phases and a
significant increase of sub-G1 events (Fig. 2E). In contrast, when the
TAp63αQ540L mutant was induced, the percentage of cells in G1 phase
was unaffected and a slight increase in S phase with a corresponding decrease
in G2-M phase was observed (Fig. 2E).
Microarray and expression analysis. The finding that wt TAp63α inhibits
cell proliferation and induces cell death, whereas the TAp63αQ540L mutant
Figure 2. The Q540L amino acid substitution impairs the ability of wild-type TAp63α to induce a G1 cell cycle arrest and cell death. Cell growth profiles of
TAp63α (A), ∆Np63α (B) and TAp63αQ540L (C) stable cell lines under induced (+ Dox) or uninduced (- Dox) conditions. The growth rate was measured
as described in Materials and methods. (D) TAp63α, ∆Np63α and TAp63αQ540L stable clones, induced (+ Dox) or uninduced (- Dox) to express the respective
p63 proteins for 3 days, were analysed for the percentage of dead cells (blue cells/total cells) by trypan blue dye staining, as described in Materials and
methods. (E) DNA content distribution of TAp63α, ∆Np63α and TAp63αQ540L cells, expressing (+ Dox) or not (- Dox) the respective p63 proteins, analysed
for DNA content by propidium iodide staining of fixed cells. Data are the mean of three independent experiments. Standard deviations are also indicated.
A B
C D
E
                                                                                                                    
lacks these capabilities prompted us to generate a comprehensive profile of
differential gene expression by microarray analysis. Four prototypic situations
were evaluated: (a) TAp63α wt without induction (b) TAp63α wt with
induction (c) TAp63αQ540L without induction (d) TAp63αQ540L with
induction. The quality of the ttlRNA extracted from H1299 stable clones
was assayed by Bioanalyzer (Agilent). Three biological replicas generated for
all four situations were used to synthesize biotinylated cRNAs for hybridiza-
tion on 12 HGU133plus2 arrays containing 54675 probesets. Microarray
data show that there is a clear upmodulation of the wt and mutant p63α
proteins upon induction with doxycycline (Fig. 3, additional tables A and
B). Upmodulation of p63α was also confirmed by qPCR (data not shown).
A total of 45 probe set ids (Fig. 3) were identified as differentially expressed
and associated with 36 gene ids, whereas the other 7 have not been assigned.
QPCR validation was done for 11 out of 36 genes. Seven (Fig. 3, Y label)
showed a perfect overlap between microarray and qPCR data, both qualita-
tively and quantitatively (i.e., same trend and similar fold change variation),
three (Fig. 3, T label) were in agreement with microarray data, except that
the fold change variation was lower, and one (Fig. 3, N label) could not be
confirmed by qPCR.
A total of ten annotated genes transactivated upon induction of wt
TAp63α (Fig. 3D) did not respond to TAp63αQ540L. Four (GDF15,
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Table 1 Primers designed to validate microarray data 
by qPCR
ACTB_FW (Endogenous control) GAGTCCGGCCCCTCCAT
ACTB_RW (Endogenous control) GCAACTAAGTCATAGTCCGCCTAGA
ARX_FW CTCGGAGCGGCAGTGTTC
ARX_RW AAAAGAGCCTGCCGAATGC
BVES_FW GGCATCTCCAAATACATTGAAAGTC
BVES_RW CGTCTTGGTAACCTGAATTCTCTCT
CDKN1A_FW CAGCGACCTTCCTCATCCA
CDKN1A_RW GCTGCTAATCAAAGTGCAATGAA
CPM_FW TGGGATTCCAGAGTTCAAATACG
CPM_RW CAGCTCCCGCCCAACAG
CTCFL_FW TGTACTTTTTCATAATGCCCAGTGA
CTCFL_RW GAGGGTGGAAAAATCTTGTCAACT
FDXR_FW TGGATGTGCCAGGCCTCTAC
FDXR_RW TGGTTGTGGCTATGACACCTGTA
FGF5_FW GCCCAGAATCAGCCCTACAA
FGF5_RW GGAGGAAGGACAAGCTCATTCTT
GDF15_FW AAACATGCACGCGCAGATC
GDF15_RW CGGTCTTTTGAATGAGCACCAT
MDM2_FW ACCACCTCACAGATTCCAGCTT
MDM2_RW GCACCAACAGACTTTAATAACTTCAAA
PMAIP1_FW TGAACTTCCGGCAGAAACTTC
PMAIP1_RW GTTTTTGATGCAGTCAGGTTCCT
POLR2B_FW (Endogenous control) CCTGATCATAACCAGTCCCCTAGA
POLR2B_RW (Endogenous control) GTAAACTCCCATAGCCTGCTTACC
PTP4A1_FW CCCTAGCATTAATTGAAGGTGGAA
PTP4A1_RW CACGCCGCTTTTGTCTTATG
Figure 3. Microarray data clustering. Hierarchical clustering, (parameters:
Euclidean distance, average linkage clustering) was performed on average
log2 fold change variation between induced and not-induced TAp63α wt
and Q540L mutant stably transfected cell lines. (A) refers to genes which are
not significantly modulated upon induction of TAp63α wt and are instead
downmodulated by TAp63αQ540L expression. (B) includes only one gene
which is downmodulated by TAp63α wt expression and not significantly
modulated by TAp63αQ540L. (C) encloses genes not significantly modulated
upon induction of TAp63α wt, but upmodulated by TAp63αQ540L. (D)
refers to genes transactivated by TAp63α wt and characterized by a loss of
regulation by TAp63αQ540L.
                                        
CDKNIA/p21/WAF, MDM2, ARX) were
selected for qPCR to determine their responsive-
ness to TAp63α, ∆Np63α and TAp63αQ540L
(Fig. 4). GDF15 and CDKNIA-p21/WAF were
significantly transactivated by TAp63α only.
GDF15 was already activated at 12 hr of induc-
tion (Fig. 4A) and p21/WAF after 24 hr (Fig. 4B).
MDM2 and ARX were similarly transactivated
by wt TA and ∆Np63α (Fig. 4C and D), but none
of these four genes were modulated by TAp63α-
Q540L (Fig. 4A and D).
We also compared the transactivation poten-
tial of TAp63α, ∆Np63α and TAp63αQ540L
protein by CAT reporter assay in H1299 cells. A
fixed amount of p21/WAF promoter-CAT
construct was transiently transfected along with
increasing amounts of plasmids encoding p63α
proteins. As shown in Figure 5A, the Q540L
mutation strongly affects the ability of TAp63α
to induce the p21/WAF gene promoter, whereas
∆Np63α is a mild activator. Western blot analysis
of the protein lysates used in this assay demon-
strated that the mutant protein was expressed at
equal, if not greater, levels than wt TAp63α
These results suggest that the difference in activity
between wt and mutated TAp63α protein was
not due to differences in protein expression (data
not shown).
The microarray data showed no increase of
p21/WAF and MDM2 endogenous proteins in
TAp63αQ540L stable cells upon induction
(Fig. 5B). Moreover, the higher the expression
of TAp63αQ540L protein in our stable clone,
the lower was the level of endogenous p21/WAF
and MDM2 proteins compared to noninduced
cells (Fig. 5B). On the other hand, both wt
TAp63α and ∆Np63α enhanced p21/WAF and
MDM2 protein levels, though to a different extent
(Fig. 5B). The same results were obtained when these
experiments were repeated on two additional inde-
pendent TAp63αQ540L stable clones isolated during
our screening (data not shown).
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Figure 5. TAp63αQ540L has lost the ability to activate
p21/WAF and MDM2 gene expression. (A) H1299
were transiently transfected with 2 µg of p21/WAF-
CAT reporter plasmid/dish alone or with different
amounts of each p63-expressing plasmid (1, 2 or 3 µg).
After 48 h, cells were harvested, and CAT activity was
determined. The basal activity of the reporter was set
at 1. The data are presented as fold induction relative
to the sample without effector (white bar). Each
histogram bar represents the mean of triplicate assays
from three independent experiments. Standard
deviations are also indicated. (B) Western blot analysis
showing expression of TAp63α wt, A p63αQ540L
and ∆Np63α proteins in stable clones at 48 h upon
induction with the indicated amounts of doxycycline.
The expression of endogenous MDM2 and p21/WAF
proteins was also evaluated by specific immunodetec-
tion. MDM2 and p21/WAF protein levels increase in
parallel with TAp63α and ∆Np63α induction, but
decrease upon TAp63αQ540L induction. β-Actin was
used as a protein loading control.
Figure 4. QPCR data related to four genes transactivated by TAp63α wt and characterized by a loss of
control by the Q540L mutant. Gene expression was analyzed at 12 and 24 hours upon addition of
doxycycline to ∆Np63α, TAp63α and TAp63αQ540L inducible cell lines. Target gene mRNA levels
were normalized for ACTB (white bars) and POL2 (black bars) and expressed as -∆∆Ct (i.e., not-induced
cell line—induced cell line Cts).
A
B
                                                                                     
TAp63α and ∆Np63α proteins are solely located in the nucleus where
they act as transcriptional factors.16 The lack of transcriptional activity of the
TAp63αQ540L protein may stem from its inability to relocalate in the
nucleus. Inspection of the subcellular location of wt TAp63α and
TAp63αQ540L in our stable clones, by immunofluorescence showed that
both proteins were uniformly distributed in the nucleus with nucleolar
sparing. Therefore the Q540L amino acid substitution does not alter
TAp63α subcellular distribution (data not shown).
TAp63αQ540L binds to p21 promoter sequences in vitro and vivo and
interacts with SP1. The absolute inability of TAp63αQ540L to transactivate
the p21/WAF promoter prompted us to find out whether it can still bind to
the p53-consensus sequence of the p21/WAF promoter. We thus compared
the DNA binding capacity of wt and mutant TAp63α isoforms by an in
vitro DNA-binding assay. A radiolabeled duplex oligonucleotide representing
a p53-binding site previously identified in the p21/WAF promoter was used
as target DNA.16 Incubation of this oligonucleotide with in vitro translated
TAp63α or TAp63αQ540L mutant led to the formation of specific protein-
DNA complexes (Fig. 6A, lanes 2 and 6). The specificity of the TAp63-
DNA complexes was tested by a competition experiment: a 100-fold cold
molar excess of the oligonucleotide completely abolished the binding, while
an irrelevant control oligonucleotide had no effect (Fig. 6, lanes 3 and 4; 7
and 8). The identity of the TAp63α-DNA complexes was confirmed by a
supershift experiment (Fig. 6A, lanes 5 and 9) in which the in vitro translated
TAp63α proteins was incubated, prior to the binding reaction, with an anti-
body recognizing the p63 DNA-binding domain. Western blot analysis
showed that the relative abundance of these proteins was comparable (data
not shown). These observations indicate that wt TAp63α specifically binds
to a p53 consensus sequence of the p21/WAF promoter and that the Q540L
mutation does not affect this binding, at least in this in vitro assay.
The promoter of the human p21/WAF gene is characterized by a set of
six proximal Sp1 binding sites located in the proximal region (nucleotides
-120 to -40) and two distal p53 binding sites. These proximal sites have
been shown to be essential for the activation of p21/WAF promoter by
p53.36 Concerning the MDM2 gene promoter, a series of five consecutive
nnGGGGC repeats, bearing similarity to the Sp1 consensus, have been
identified (nucleotides -415 to -318). These conserved GC elements contribute
to the basal activity of the p53-inducible MDM2 promoter.37 Since it has
previously been reported that the γ isoform of TAp63α directly interacts
with Sp1, we decided to determine whether TAp63α is also able to interact
with Sp1 and, if so, the effect of the Q540L substitution. We performed
coimmunoprecipitation experiments in TAp63α and TAp63αQ540L
expressing cell lines, both Dox-induced and not. As shown in Figure 6B,
both wt and mutant TAp63α proteins were immunoprecipitated by a Sp1
polyclonal antibody. Reciprocal immunoprecipitation, which detects Sp1
protein with the p63 monoclonal antibody, did not immunoprecipitate Sp1
(data not shown).
DISCUSSION
Epithelial development and differentiation in embryo rely on a
set of temporally and spatially regulated molecular events. Recent
observations designate p63 as a driving force of this process: the
∆Np63α isoform maintains the proliferative potential of basal
keratinocytes in mature epidermis, whereas the TAp63α isoform,
which is the first to be expressed in mouse embryo, is believed to act
as a molecular switch required for commitment to epithelial stratifi-
cation.3 A broad spectrum of p63 mutations are responsible for
several human ectodermal, craniofacial and limb malformations.20
EEC and ADULT mutations are located in the DB domain of p63.
They abolish p63 DNA-binding and produce highly stable, but
transactivation-inert TAp63 proteins.38 AEC mutations are confined
to the SAM domain.22 Their effects on p63 transcriptional functions
are less predictable and they only affect the α isoforms.
The Q540L mutation impairs p63 transcriptional ability. Our
study provides evidence that the Q540L amino acid substitution
strongly impairs the transcriptional activity of TAp63α (Figs. 3 and 4).
Our genome-wide transcriptional profiles comparing the transcrip-
tional response induced by wt and TAp63αQ540L expression show
that 14 out of 45 differentially modulated probe sets (ten annotated
genes), are characterized by a loss of control (activation or repression)
by the Q540L mutant (Fig. 3D). As demonstrated (see Fig. 2, qPCR
and data not shown) the lack of transactivation ability of
TAp63αQ540L cannot be attributed to a decrease in its expression,
nor to alteration of its subcellular location. It is well documented
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Figure 6. TAp63αQ540L binds to p53 consensus site in the p21/WAF target promoter and associates with the Sp1 transcription factor. (A) The indicated
p63 proteins were in vitro translated by using TnT reticulocytes from Promega and 0.5 µ of each p63 plasmid DNA. Equal amounts of the individual
reactions were subjected to EMSA using a 32P-labeled oligo containing a p53-binding site present in the p21 promoter (p21.1 probe). Cold competition
was performed with either the 100-fold molar excess of the same oligonucleotide (lanes 3 and 7) or an oligonucleotide containing a consensus binding
site for E2F1 (lanes 4 and 8). For the supershift, anti-p63 antibodies (4A4; SantaCruz) were added to the sample prior to the binding reaction (lanes 5 and 9).
(B) Coimmunoprecipitation in TAp63α and TAp63αQ540L expressing cell lines. Both wt and mutant TAp63α proteins were immunoprecipitated by a Sp1
polyclonal antibody only upon their induction with doxycycline.
A B
                                                                             
that, p63, like p73, can bind to the p53 consensus DNA-binding
motif and activate a number of p53-regulated genes. In principle,
the Q540L mutation, even though it is predicted to not destroy the
overall structure of the SAM domain, could alter the DNA-binding
affinity of the mutant protein. As regulation of p21/WAF was
severely impaired in cells expressing the Q540L mutant, we tested
whether the mutant protein was still capable of interacting with a
p53-binding motif of the p21/WAF promoter. Our results indicate
that both wt TAp63α and its Q540L mutant are equally active in
binding to this sequence, at least in our in vitro system. On the other
hand, several data argue that particular coactivators expressed in
specific cell types and factors bound to the promoters confer speci-
ficity of gene regulation on the members of the p53 family and their
isoforms.39 For instance, ∆Np63α negatively regulates transcription
of the hsp70 promoter through its interaction with the CCAAT-
binding and NF-Y transcription factors,40 while Sp1 cooperates with
p53, p63 and p73 in synergistic transactivation of the p21/WAF
promoter.36 As a physical interaction between TAp63α and Sp1
takes place and is required for the regulation of EGFR gene expres-
sion,41 we determined whether TAp63α also interacts with Sp1 and,
if so, the effect of the Q540L substitution. Our data clearly indicate
that TAp63Q540L is still able to interact with Sp1 (Fig. 6B). Other
transcriptional factors may thus be crucial for p63-driven transcription
and the Q540L amino acid substitution may affect the interaction
between the p63 SAM domain and a still undefined factor.
Furthermore, we also found probe sets that are specifically up or
downregulated by the mutant protein alone (Fig. 3A and C). These
apparently conflicting results, too, may be a consequence of a loss of
transcriptional function, assuming that the above-mentioned genes
are p63 secondary targets repressed or activated by p63 primary targets.
Alternatively, the possibility that the Q540L aminoacid substitution
confers new transcriptional and cell growth regulating properties on
the TAp63α protein by altering its ability to interact with particular
coactivators or corepressors cannot be ruled out.
This possibility needs investigated by comparing the activity of
wt and mutant proteins directly on the promoters of these TAp63α-
Q540L-regulated genes by means of transient reporter assays.
Furthermore, other technologies, such as in vivo DNA-binding
assays and mass spectrometry, will aid in the identification of key
proteins involved in the regulation of p63’s transcriptional activities.
Differentially expressed genes and their implication in AEC
pathogenesis. An extensive search of the published literature to find
links between the physiological functions of the deregulated genes
and their role in AEC showed that, with the exception of p21/WAF
and MDM2, they were the subject of very few publications and little
was known about their functions. It was, however, found that GDF15,
BVES, CLMN and CPM are involved in the mechanisms of cell
differentiation,42-45 while ARX and FGF5 are associated with
embryonic development.46-49 GDF15 is the murine ortholog of the
human immunoregulatory cytokine macrophage inhibitory cytokine-1
(MIC-1) also known as PDF (prostate derived factor), a divergent
TGF-β superfamily member. It has proapoptotic and antimitotic
activities and is involved in the control of prostatic cell growth.44
Interestingly, the GDF15 promoter contains two putative p53
responsive elements and is upregulated by p53, though its expression
in response to injury also appears to be induced p53-independently.50,51
GDF15 seems to be a p63 target, specifically upregulated by
TAp63α (Fig. 4D). This regulation is completely abolished by the
Q540L amino acid substitution (Fig. 3D). The lack of GDF15
expression in epithelia may contribute to the abnormal differentiation
of epithelia-derived structures observed in AEC patients.
Another gene closely involved in development is ARX.47 Its
expression profile is highly complex and dynamic in the mouse
embryo brain, where it peaks at embryonic (E) day 9.5 just after the
TAp63α expression peak (E. 8.5).3 It is also a marker of adult neu-
ronal stem cells.47 Interestingly, both TAp63α and ARX transcripts
decrease at E 13.5, which corresponds to the switch from TAp63α
to ∆Np63α expression.3 Our transcriptional profiling combined
with the published data on ARX suggests that p63 and ARX may be
linked in a common regulatory pathway. The information available,
however, is not sufficient to allow a direct connection to be made
between the function of p63 and ARX in AEC.
Calmin (CLMN) is a protein with calponin homology (CH
domain) and transmembrane domains expressed in maturing sper-
matogenic cells. The cDNA encoding CLMN was isolated by RNA
differential display applied to developing mouse skin. The region
covering the CH domain showed a high level of homology with
β-spectrin, α-actinin, and dystrophin. The CLMN transcript was
detected in adult testis, liver, kidney, and large intestine; the expression
in testis was by far the strongest.42 CLMN is linked to skin develop-
ment. In mice, its mRNA starts to be detectable in the epidermis at
15.5–16.5 dpc (days post-coitum) and its expression increases as the
skin develops. The timing of CLMN gene expression corresponds to
the switch from the TA to the ∆N isoform. CLMN is only transacti-
vated by the Q540L mutant (Fig. 3C). Since induction of CLMN
expression fits in nicely with the timing of the switch from TAp63α
to ∆Np63α expression in the epithelial stratification program,3
TAp63α may be supposed to act as a transcriptional repressor of this
gene, with the result that expression of mutant TAp63α might
improperly anticipate CLMN expression during skin development.
BVES/Pop1 is the prototype of a new class of cell adhesion
molecules. It is expressed in the epithelial components of retina, lens
and cornea,52 during blood vessel development, in the gut endoderm
and the epicardium and in all three germ layers during avian organo-
genesis.53 BVES is transactivated by TAp63α and not modulated by
the Q540L mutant, and hence may be required to promote cell
adhesion and translocation during early embryogenesis.
Another interesting gene that is only transactivated by the mutant
p63 is SERPINH1, also known as HSP47. Hsp47 protein is involved
in skin wound regeneration and immunohistochemistry has demon-
strated Hsp47-positive cells in the epidermal cell layer of fetal and
neonatal rat skin. Hsp47 may be an important determinant of scar
formation, since scarless healing of fetal skin wounds correlates with
a lack of change in HSP47 expression.54
p21/WAF has long been known to arrest the cell cycle. In the
epithelium it is involved in maintenance of the stem cell compart-
ment:55 p21 null mice are unable to limit the production of stem
cells and their proliferative potential.55 p21/WAF is strongly transac-
tivated by the TAα wild-type isoform (Fig. 4A) and its promoter is
not or only mildly responsive to the ∆Nα isoform.27 By inducing
p21/WAF, TAp63α breaks the cell cycle by restraining stem cell
proliferation: the overall system is committed to the formation of
stratified epithelia. The parallel increase of ∆Nα and decrease of
TAp63α expression redirects the system to terminal differentiation.27
Our qPCR data (Fig. 4B) and expression studies (Figs. 3D and 5B)
support this scenario since the p21/WAF promoter is strongly
activated by the TAp63α wt isoform and p21/WAF upmodulation
is reduced if ∆Np63α is expressed. Interestingly, while ∆Np63α
seems less efficient than TAp63α as a p21/WAF activator (Figs. 4B
and 5B), they both induce a similar G1 cell cycle arrest. The
aminoterminal-deleted isoform should not be generally defined as a
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transactivation-defective isoform. Our and other published data
indicate that ∆Np63α modulates transcription40 and this ability is
rather dependent on the specific gene promoter (see Fig. 4C and D).
In conclusion, the difference in the growth rate profiles (Fig. 2A and
B) of cells expressing either the TA or the ∆Np63α isoforms is likely
to be the result of the relatively higher efficiency of TAp63α with
respect to ∆Np63α in inducing cell death, as shown in Figure 2D.
The growth rate profiles and cell cycle distribution of cells
expressing the AEC-derived TAp63α protein are undistinguishable
from those of uninduced cells (Fig. 2C and E), indicating that the
Q540L amino acid substitution affects both the cell cycle arrest and
cell death inducing properties of p63. Finally, we suggest that dereg-
ulation of p21/WAF associated with the Q540L mutation will produce
a defect in the process of commitment to epithelial stratification that
simultaneously allows premature expression of skin differentiative
markers. A defect of this kind would explain the skin fragility and
chronic scalp erosions complicated by infections, which are a hallmark
of AEC. In conclusion, further investigation of the differentially
regulated genes identified in this study will result in a better under-
standing of the molecular mechanism underlying the AEC phenotype.
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